Drug Trial Radar · NCT05636215
A First-in-human Study of IBI354 in Subjects with Locally Advanced Unresectable or Metastatic Solid Tumors
Last checked: Nov 19, 2026Latest source record: Mar 20, 2025 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Recruiting
Enrollment
368
Planned (sponsor's estimate)
Start
Apr 4, 2023
Primary completion
Apr 30, 2025
Study completion Oct 31, 2025
Sponsor
- Lead sponsor
- Innovent Biologics (Suzhou) Co. Ltd.Industry
- Sponsor type
- Industry
- First posted
- Dec 5, 2022
Design
- Study type
- Interventional
- Phase
- Phase 1 / Phase 2
- Allocation
- Not applicable (single group)
- Model
- Single group
- Masking
- None
- Primary purpose
- Treatment
- FDA-regulated drug
- No
- Who can join
- All sexes, from 18 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
This is a Phase 1/2, open-label, multicenter study designed to evaluate the safety, tolerability, and DLTs to establish the maximum tolerated dose (MTD) or maximum administered dose (MAD), and the RP2D of sequential doses of IBI354 (study drug), and to explore and confirm the efficacy, safety and tolerability of IBI354 in subjects with locally advanced unresectable or metastatic solid tumors.
Conditions
- Locally Advanced Unresectable or Metastatic Solid Tumors
Interventions
IBI354Biological
Recombinant Anti-HER2 monoclonal Antibody-Camptothecin derivative conjugate for injection
Primary outcomes
What the sponsor says the trial is designed to measure.
- Incidence of serious adverse events (SAEs), treatment-emergent AEs (TEAEs).Time frame: Up to 30 days after the last administration
- Number of dose-limiting toxicity (DLT)Time frame: 21 days during the first cycle in Phase Ia
Locations
6 sites in 2 countries. Site status is shown where the registry gives one.
Scientia Clinical Research Ltd
Randwick, New South Wales, Australia · Completed
Westmead Hospital
Sydney, New South Wales, Australia · Completed
Sunshine Coast University Private Hospital
Sunshine Coast, Queensland, Australia · Completed
Monash Health
Clayton, Victoria, Australia · Completed
Peking University Cancer Hospital
Beijing, Beijing Municipality, China · Recruiting
Affiliated Cancer Hospital of Chongqing University
Chongqing, Chongqing Municipality, China · Recruiting
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.